TICKERNERD
Menu
GDRXGDRXHealthcare · Health Information Services

GDRX Stock Forecast: GoodRx Holdings, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$3.45
−3.09% on the day

The 15 Wall Street analysts covering GoodRx Holdings, Inc. hold a median 12-month price target of $4 — +15.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.2B
Ticker Nerd rank
75 / 100
Median analyst target
$4.00
Analysts covering
15
Total return, dividends reinvested
1W
−7.5%
1M
+14.2%
YTD
+27.3%
1Y
−23.2%
From 52W high
−31.4%
From 52W low
+84.5%
$1.87
$5.03
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GDRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores GoodRx Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
75 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
92
Value
91
Accruals
77
Quality
73
Volatility
66
Revisions
61
Size
43
Momentum
33
Growth
18

Issuance (92): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GDRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GDRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26GDRXHigh $5.00Median $4.00Low $2.65

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
5 Buy8 Hold2 Sell
Low $2.65Median $4.00High $5.00

The green dot is the last close — the median target sits +15.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
21 Aug 2026BarclaysMaintainsUnderweight$3.00 → $4.00
13 Aug 2026UBSMaintainsNeutral$2.50 → $3.75
11 Aug 2026CitigroupMaintainsBuy$4.00 → $5.00
11 Aug 2026TD CowenMaintainsBuy$4.00 → $5.00
7 Aug 2026Wells FargoMaintainsOverweight$3.50 → $5.00
14 May 2026CitigroupMaintainsBuy$3.50 → $4.00
14 May 2026CitigroupMaintainsBuy—
11 May 2026TD CowenMaintainsBuy$3.00 → $4.00
11 May 2026TD CowenMaintainsBuy—
4 Mar 2026Wells FargoMaintainsOverweight—
3 Mar 2026CitigroupMaintainsBuy—
2 Mar 2026Goldman SachsMaintainsNeutral—
27 Feb 2026JP MorganDowngradeNeutral—
27 Feb 2026MizuhoMaintainsNeutral—
22 Jan 2026JefferiesDowngradeHold—
9 Jan 2026CitigroupMaintainsBuy—
18 Dec 2025Morgan StanleyMaintainsEqual-Weight—
9 Dec 2025BarclaysInitiatesUnderweight—
11 Nov 2025JP MorganMaintainsOverweight—
10 Nov 2025TD CowenMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GDRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

GDRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−5.0%
Analysts raising
2
Analysts cutting
2
Fundamentals

GoodRx Holdings, Inc. (GDRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
57.5×

Cheaper than 13% of US stocks

Price / sales
1.5×

Cheaper than 60% of US stocks

Price / book
1.8×

Cheaper than 49% of US stocks

EV / EBITDA
13.1×

Cheaper than 27% of US stocks

Growth & margins
Revenue growth (YoY)
−1.3%

Higher than 25% of US stocks

Earnings growth (YoY)
−33.5%

Higher than 14% of US stocks

Gross margin
89.5%

Higher than 96% of US stocks

Operating margin
11.8%

Higher than 67% of US stocks

Net margin
2.1%

Higher than 52% of US stocks

Returns & dividend
Return on equity
2.5%

Higher than 49% of US stocks

Return on assets
3.0%

Higher than 65% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

GDRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
GDRXGoodRx Holdings, Inc.$1.2B
75
TDOCTeladoc Health, Inc.$1.1B
68
CERTCertara, Inc.$1.3B
55
OMDAOmada Health, Inc.$1.4B
85
SDGRSchrödinger, Inc.$1.5B
53
TALKTalkspace, Inc.$879.4M
—
OMCLOmnicell, Inc.$1.6B
98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own GoodRx Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GDRX news & analysis

GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope

Seeking Alpha · 12 Aug 2026neutral

GoodRx's stock has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. Direct brand launches and new subscription plans have contributed to the recent positive developments, though the author remains only marginally more positive and notes considerable risk, keeping a neutral rating.

Why it matters — A GDRX watcher would care because the stock's recovery and new product initiatives signal improving momentum, even as the analyst maintains a cautious, neutral stance due to remaining risk.

Push for 'COMPETITIVE CASH PRICING': GoodRx CEO on TrumpRx partnership

Fox Business · 7 Aug 2026positive

GoodRx CEO Wendy Barnes discussed the company's partnership with TrumpRx and its efforts to lower prescription drug costs in an interview on Fox Business' "The Claman Countdown." The discussion centered on the push for competitive cash pricing for prescription drugs.

Why it matters — The TrumpRx partnership and pricing initiatives reflect GoodRx's efforts to expand its role in lowering prescription drug costs, which is central to its business model.

GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for GoodRx Holdings, Inc. (GDRX). The item identifies and provides the company's earnings call transcript for the quarter but offers no additional detail or commentary.

Why it matters — GDRX watchers rely on earnings call transcripts for management commentary on the company's quarterly performance and outlook.

GoodRx Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

GoodRx reported second-quarter 2026 revenue of $200.4 million and adjusted EBITDA of $63.7 million, a 31.8% adjusted EBITDA margin. Growth in its Pharma Direct and subscription businesses offset ongoing pressure in prescription transaction revenue.

Why it matters — The results show GoodRx's ability to grow revenue and margins through diversification even as its core prescription transaction segment faces continued headwinds.

GoodRx and Oscar Health Tout Tech as Consumer Needs Change

PYMNTS · 6 Aug 2026neutral

An earnings report covering Oscar Health and GoodRx shows both companies addressing a changing customer base. Oscar Health reported record profitability for the first six months of 2026, with revenues up 70% to $4.9 billion.

Why it matters — For GoodRx watchers, the report highlights how both companies are leaning on technology as consumer needs shift, providing context for GoodRx's own earnings.

FAQ

Frequently asked questions about GDRX stock

What is the GDRX stock price forecast for 2026-2027?

The 15 Wall Street analysts covering GoodRx Holdings, Inc. have a median 12-month price target of $4, with estimates ranging from $2.65 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GDRX stock a buy right now?

Of the 15 analysts covering GoodRx Holdings, Inc., 5 rate it a Buy, 8 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks GoodRx Holdings, Inc. 75 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GDRX?

As at 22 Aug 2026, GoodRx Holdings, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (92 of 100).

Will GDRX stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +15.9% from the last close, and Ticker Nerd's factor model ranks GoodRx Holdings, Inc. 75 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GDRX stock forecast for 2030?

No analyst covering GoodRx Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GDRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.65 to $5 over the next 12 months.

How has GDRX stock performed over the past year?

GoodRx Holdings, Inc. returned -23.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GoodRx Holdings, Inc. do?

GoodRx Holdings, Inc. is a healthcare technology company that offers digital tools to help consumers compare prices and reduce out-of-pocket costs for prescription medications in the United States.

What is the latest news on GDRX?

The most recent item we track (Seeking Alpha, 12 Aug 2026): "GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope". GoodRx's stock has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. Direct brand launches and new subscription plans have contributed to the recent positive developments, though the author remains only marginally more positive and notes considerable risk, keeping a neutral rating.

Company

About GoodRx Holdings, Inc.

GoodRx Holdings, Inc. is a healthcare technology company that offers digital tools to help consumers compare prices and reduce out-of-pocket costs for prescription medications in the United States. The company’s core platform aggregates and curates geographically relevant prescription pricing, giving users access to discounts and negotiated rates at pharmacies nationwide. Beyond prescription savings, GoodRx Holdings, Inc. provides subscription-based services, solutions for pharmaceutical manufacturers, and telehealth offerings through its GoodRx Care platform, expanding its reach across the broader outpatient healthcare ecosystem. The company also addresses the pet health segment by supporting prescription-related products and services for animals. Operating at the intersection of healthcare, technology, and data, GoodRx Holdings, Inc. plays a significant role in improving price transparency and affordability in the U.S. prescription market, serving consumers, pharmacy benefit managers, pharmacies, and life sciences companies. Founded in 2011 and headquartered in Santa Monica, California, it has become a notable participant in the health care technology sector.

CEO Ms. Wendy Barnes · 697 employees · United States · https://www.goodrx.com